NEUP
NASDAQ · Biotechnology
Neuphoria Therapeutics Inc
$3.85
+0.02 (+0.52%)
Open$3.84
Previous Close$3.83
Day High$3.88
Day Low$3.83
52W High$21.40
52W Low$3.19
Volume—
Avg Volume105.6K
Market Cap21.08M
P/E Ratio—
EPS$-8.77
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+284.2% upside
Current
$3.85
$3.85
Target
$14.79
$14.79
$9.77
$14.79 avg
$16.23
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 51.84M | 5.17M | 4.87M |
| Net Income | -1,225,950 | -354,866 | -256,361 |
| Profit Margin | -2.4% | -6.9% | -5.3% |
| EBITDA | -1,544,267 | -507,265 | -425,609 |
| Free Cash Flow | — | -183,163 | -132,058 |
| Rev Growth | +696.2% | -7.1% | +6.1% |
| Debt/Equity | 0.00 | 0.39 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |